{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T16:15:16Z","timestamp":1778516116052,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["KLI 480-B30"],"award-info":[{"award-number":["KLI 480-B30"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["F 3513-B20"],"award-info":[{"award-number":["F 3513-B20"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100025010","name":"Dipartimento di Scienze del Farmaco, Universit\u00e0 degli Studi di Padova","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100025010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003065","name":"Universit\u00e4t Wien","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ejps.2026.107441","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T16:15:02Z","timestamp":1768407302000},"page":"107441","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["In vivo evidence of functional OATP2B1 activity in human skeletal muscle using [11C]erlotinib PET"],"prefix":"10.1016","volume":"218","author":[{"given":"Matthias","family":"Jackwerth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Severin","family":"Mairinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"Hacker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Tournier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Zeitlinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4048-5781","authenticated-orcid":false,"given":"Oliver","family":"Langer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2026.107441_bib0001","doi-asserted-by":"crossref","first-page":"486","DOI":"10.2967\/jnumed.118.216432","article-title":"A proof-of-concept study to inhibit ABCG2- and ABCB1-mediated efflux transport at the human blood-brain barrier","volume":"60","author":"Bauer","year":"2019","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejps.2026.107441_bib0002","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/cpt.888","article-title":"Influence of OATPs on hepatic disposition of erlotinib measured with positron emission tomography","volume":"104","author":"Bauer","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2026.107441_bib0003","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1021\/acs.molpharmaceut.8b00588","article-title":"Effect of rifampicin on the distribution of [11C]erlotinib to the liver, a translational PET study in humans and in mice","volume":"15","author":"Bauer","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2026.107441_bib0004","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/cpt.1506","article-title":"PET imaging of [11C]rosuvastatin hepatic concentrations and hepatobiliary transport in humans in the absence and presence of cyclosporine A","volume":"106","author":"Billington","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2026.107441_bib0005","doi-asserted-by":"crossref","first-page":"8163","DOI":"10.1158\/0008-5472.CAN-06-0453","article-title":"Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib","volume":"66","author":"Carey","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejps.2026.107441_bib0006","doi-asserted-by":"crossref","DOI":"10.1128\/MCB.00140-19","article-title":"Soluble heparin binding Epidermal Growth Factor-Like Growth Factor is a regulator of GALGT2 expression and GALGT2-dependent muscle and neuromuscular phenotypes","volume":"39","author":"Cramer","year":"2019","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.ejps.2026.107441_bib0007","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41573-023-00877-1","article-title":"Membrane transporters in drug development and as determinants of precision medicine","volume":"23","author":"Galetin","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejps.2026.107441_bib0008","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s00424-014-1596-x","article-title":"Differential cellular expression of organic anion transporting peptides OATP1A2 and OATP2B1 in the human retina and brain: implications for carrier-mediated transport of neuropeptides and neurosteriods in the CNS","volume":"467","author":"Gao","year":"2015","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.ejps.2026.107441_bib0009","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"Giacomini","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejps.2026.107441_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmr.2024.100023","article-title":"Organic anion transporting polypeptides: pharmacology, toxicology, structure, and transport mechanisms","volume":"77","author":"Hagenbuch","year":"2025","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejps.2026.107441_bib0011","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1111\/bph.17449","article-title":"Silencing drug transporters in human primary muscle cells modulates atorvastatin pharmacokinetics: a pilot study","volume":"182","author":"Hoste","year":"2025","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejps.2026.107441_bib0012","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1124\/dmd.114.059097","article-title":"Selective inhibition of human solute carrier transporters by multikinase inhibitors","volume":"42","author":"Johnston","year":"2014","journal-title":"Drug. Metab. Dispos."},{"key":"10.1016\/j.ejps.2026.107441_bib0013","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1021\/jm300212s","article-title":"Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions","volume":"55","author":"Karlgren","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2026.107441_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114534","article-title":"OATP2B1 - The underrated member of the organic anion transporting polypeptide family of drug transporters?","volume":"188","author":"Kinzi","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejps.2026.107441_bib0015","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1161\/CIRCRESAHA.109.203596","article-title":"Human skeletal muscle drug transporters determine local exposure and toxicity of statins","volume":"106","author":"Knauer","year":"2010","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejps.2026.107441_bib0016","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/jcbfm.1990.127","article-title":"Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects","volume":"10","author":"Logan","year":"1990","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.ejps.2026.107441_bib0017","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1158\/1535-7163.MCT-07-2250","article-title":"Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-\/-\/Mdr1a\/1b-\/- (triple-knockout) and wild-type mice","volume":"7","author":"Marchetti","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejps.2026.107441_bib0018","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.pharmthera.2018.12.009","article-title":"Organic anion transporting polypeptide 2B1 - More than a glass-full of drug interactions","volume":"196","author":"McFeely","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2026.107441_bib0019","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1006\/dbio.1995.0012","article-title":"Synapse-associated expression of an acetylcholine receptor-inducing protein, ARIA\/heregulin, and its putative receptors, ErbB2 and ErbB3, in developing mammalian muscle","volume":"172","author":"Moscoso","year":"1995","journal-title":"Dev. Biol."},{"key":"10.1016\/j.ejps.2026.107441_bib0020","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/psp4.13139","article-title":"Physiologically based pharmacokinetics modeling and transporter proteomics to predict systemic and local liver and muscle disposition of statins","volume":"13","author":"Prieto Garcia","year":"2024","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.ejps.2026.107441_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100069","article-title":"Erlotinib-A substrate and inhibitor of OATP2B1: pharmacokinetics and CYP3A-mediated metabolism in rSlco2b1\u2212\/\u2212 and SLCO2B1+\/+ rats","volume":"53","author":"Rysz","year":"2025","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2026.107441_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2024.106852","article-title":"Preincubation-dependent inhibition of organic anion transporting polypeptide 2B1","volume":"200","author":"Sinokki","year":"2024","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2026.107441_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2025.103772","article-title":"In vitro characterization of SLCO2B1 genetic variants","volume":"114","author":"Sinokki","year":"2025","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2026.107441_bib0024","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.pharmthera.2018.04.006","article-title":"Imaging techniques to study drug transporter function in vivo","volume":"189","author":"Tournier","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2026.107441_bib0025","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.nucmedbio.2017.05.007","article-title":"[11C]Erlotinib PET cannot detect acquired erlotinib resistance in NSCLC tumor xenografts in mice","volume":"52","author":"Traxl","year":"2017","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.ejps.2026.107441_bib0026","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1471-4159.2011.07208.x","article-title":"Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors","volume":"117","author":"Uchida","year":"2011","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejps.2026.107441_bib0027","first-page":"488","article-title":"Clinically relevant OATP2B1 inhibitors in marketed drug space","volume":"17","author":"Unger","year":"2020","journal-title":"Mol. Pharm."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726000151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726000151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T16:06:15Z","timestamp":1778515575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098726000151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":27,"alternative-id":["S0928098726000151"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107441","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vivo evidence of functional OATP2B1 activity in human skeletal muscle using [11C]erlotinib PET","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107441","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107441"}}